Comparing Valion Bio, Inc. Common Stock (VBIO) & Its Rivals

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Valion Bio, Inc. Common Stock to similar businesses based on the strength of its dividends, profitability, analyst recommendations, risk, institutional ownership, valuation and earnings.

Profitability

This table compares Valion Bio, Inc. Common Stock and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Valion Bio, Inc. Common Stock N/A -193.17% -67.10%
Valion Bio, Inc. Common Stock Competitors -12,224.09% -202.33% -31.23%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Valion Bio, Inc. Common Stock and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valion Bio, Inc. Common Stock 1 0 0 0 1.00
Valion Bio, Inc. Common Stock Competitors 9919 15313 45656 1602 2.54

As a group, “Biotechnology” companies have a potential upside of 126.25%. Given Valion Bio, Inc. Common Stock’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Valion Bio, Inc. Common Stock has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 0.9% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Valion Bio, Inc. Common Stock and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Valion Bio, Inc. Common Stock $780,000.00 -$8.88 million -0.00
Valion Bio, Inc. Common Stock Competitors $720.07 million $10.07 million -18.81

Valion Bio, Inc. Common Stock’s competitors have higher revenue and earnings than Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Valion Bio, Inc. Common Stock has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Valion Bio, Inc. Common Stock’s competitors have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Summary

Valion Bio, Inc. Common Stock competitors beat Valion Bio, Inc. Common Stock on 9 of the 13 factors compared.

Valion Bio, Inc. Common Stock Company Profile

(Get Free Report)

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.